On October 4, 2022 TrialSpark reported a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently (Press release, Sanofi, OCT 4, 2022, View Source [SID1234621761]). The collaboration will focus on jointly pursuing the acquisition/in-licensing and development of best-in-class, clinical-stage Phase II and Phase III drug candidates in areas of high unmet patient need.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The partnership aims to leverage Sanofi’s global commercial expertise and TrialSpark’s tech-enabled drug development capabilities, exploring new and innovative models of clinical development, such as behavioral intervention and digital technologies to achieve better patient outcomes.
Sanofi + TrialSpark will jointly pursue the acquisition/in-licensing and development of Phase II & III drug candidates
"We are excited to initiate this novel collaboration with TrialSpark, as another example of our commitment to innovation in the healthcare ecosystem" said, Alban de La Sablière, Partnering Head, Sanofi. "This collaboration will not only identify attractive late-stage assets, but will also use innovative development plans which could bring meaningful outcomes to patients in areas of mutual interest."
"It is a privilege to partner with Sanofi to jointly acquire and develop new treatments," said Benjamine Liu, TrialSpark’s CEO and Co-Founder. "Sanofi is a world leader in drug development, with extensive global commercial expertise. TrialSpark is delighted to have such an exceptional partner to work together with on bringing new treatments to patients faster than ever before."
The Sanofi and TrialSpark partnership formally launched in September 2022, jointly targeting six transactions over the course of the next three years.